Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

doi:10.1016/j.clml.2026.02.004

Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

2026-02-14

0

OA

AI

Juan Carlos Hernández‐Boluda

DOI：10.1016/j.clml.2026.02.004

Original

Save

View PDF

Abstract

En 中文

• Post hoc analysis of the anemic subpopulation of the phase 3 SIMPLIFY-1 trial • Spleen responses with momelotinib vs ruxolitinib were comparable in anemic patients • Baseline platelet count <200×109/L was a differentiator in favor of momelotinib • Dual spleen response and transfusion independence rates were higher with momelotinib • Transfusion independence with or without spleen response predicted longer survival

Keywords:

anemia

momelotinib

myelofibrosis

ruxolitinib

platelet counts

spleen response

survival

transfusion independence

Spleen volume reduction and transfusion independence with momelotinib vs ruxolitinib and associated overall survival with momelotinib in JAK inhibitor–naive patients with myelofibrosis and anemia: subgroup analyses of SIMPLIFY-1

Abstract

AI Summary

Journal

Organization